A small study suggests the use of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL) with secondary central nervous system (CNS) involvement is safe ...

A review article examines questions about sequencing treatments in light of recent developments in relapsed/refractory mantle cell lymphoma. Treatment approaches have shifted with the introduction of ...

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma Eligible ...

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell ...

A blockbuster AstraZeneca drug may now be used as an earlier treatment for mantle cell lymphoma (MCL), making it the first in its class approved as a first-line therapy for this rare and aggressive ...

Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms Patients with cBTKi pretreated relapsed/refractory (R/R) MCL received pirtobrutinib monotherapy in a multicenter ...

As in CLL, immunoglobulin heavy chain genes are mutated in a subset of MCL patients, but, in contrast to CLL, this does not seem to correlate with outcome. Recent data, however, suggest that using a ...

Calquence, a BTK inhibitor, is now approved for first-line treatment of MCL, offering a new therapeutic option for patients ineligible for stem cell transplantation. The ECHO trial showed significant ...

Mantle cell lymphoma is a cancer that often goes through phases of remission and relapse. During remission, doctors will continue to monitor a person for signs of relapse. They may also use certain ...